SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________________
FORM 10-Q/A
(Amendment No. 1)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
OR
For the quarterly period ended June 30, 1996
Commission File No. 0-15360
BIOJECT MEDICAL TECHNOLOGIES INC.
(Exact name of registrant as specified in its charter)
Oregon 93-1099680
(State of other jurisdiction of (I.R.S. identification no.)
employer incorporation or organization)
7620 SW Bridgeport Road
Portland, Oregon 97224
(Address of principal executive offices) (Zip code)
(503) 639-7221
(Registrant's telephone number, including areas code)
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act
of 1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to
such filing requirements for the past 90 days. Yes [X] No [ ]
At June 30, 1996 there were 15,616,712 outstanding shares of common stock
of the registrant.
<PAGE>
INDEX TO EXHIBITS
Exhibit No. Exhibit Description
- ----------- -------------------------------
27 Financial Data Schedule
<PAGE>
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
BIOJECT MEDICAL TECHNOLOGIES INC.
(Registrant)
Date: October 2, 1996 /S/ Peggy J. Miller
---------------------------------
Peggy J. Miller
Vice President and Chief Financial Officer
<TABLE> <S> <C>
<ARTICLE> 5
<MULTIPLIER> 1
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> MAR-31-1996
<PERIOD-END> JUN-30-1996
<CASH> 2,753,489
<SECURITIES> 0
<RECEIVABLES> 72,710
<ALLOWANCES> 0
<INVENTORY> 1,517,180
<CURRENT-ASSETS> 4,391,161
<PP&E> 2,728,804
<DEPRECIATION> 1,213,338
<TOTAL-ASSETS> 6,381,184
<CURRENT-LIABILITIES> 968,437
<BONDS> 450,000
0
0
<COMMON> 36,160,508
<OTHER-SE> 0
<TOTAL-LIABILITY-AND-EQUITY> 6,381,184
<SALES> 176,869
<TOTAL-REVENUES> 491,769
<CGS> 581,542
<TOTAL-COSTS> 581,542
<OTHER-EXPENSES> 1,134,123
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 0
<INCOME-PRETAX> (1,223,896)
<INCOME-TAX> 0
<INCOME-CONTINUING> (1,223,896)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (1,223,896)
<EPS-PRIMARY> (.08)
<EPS-DILUTED> (.08)
</TABLE>
